| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9259428 | MYLAN SPECIALITY LP | Combination of azelastine and fluticasone for nasal administration |
Jun, 2023
(10 months ago) | |
| US9901585 | MYLAN SPECIALITY LP | Combination of azelastine and fluticasone for nasal administration |
Jun, 2023
(10 months ago) | |
| US8163723 | MYLAN SPECIALITY LP | Combination of azelastine and steroids |
Aug, 2023
(8 months ago) | |
|
US9259428 (Pediatric) | MYLAN SPECIALITY LP | Combination of azelastine and fluticasone for nasal administration |
Dec, 2023
(4 months ago) | |
|
US8163723 (Pediatric) | MYLAN SPECIALITY LP | Combination of azelastine and steroids |
Feb, 2024
(2 months ago) | |
| US8168620 | MYLAN SPECIALITY LP | Combination of azelastine and steroids |
Feb, 2026
(1 year, 9 months from now) | |
|
US8168620 (Pediatric) | MYLAN SPECIALITY LP | Combination of azelastine and steroids |
Aug, 2026
(2 years from now) | |
Dymista is owned by Mylan Speciality Lp.
Dymista contains Azelastine Hydrochloride; Fluticasone Propionate.
Dymista has a total of 7 drug patents out of which 5 drug patents have expired.
Expired drug patents of Dymista are:
- US9259428
- US9901585
- US8163723
- US9259428*PED
- US8163723*PED
Dymista was authorised for market use on 01 May, 2012.
Dymista is available in spray, metered;nasal dosage forms.
Dymista can be used as relief of symptoms associated with seasonal allergic rhinitis, treatment of seasonal allergic rhinitis.
The generics of Dymista are possible to be released after 24 August, 2026.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Feb 20, 2018 |
| Pediatric Exclusivity(PED) | Aug 20, 2018 |
| New Combination(NC) | May 01, 2015 |
Drugs and Companies using AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 01 May, 2012
Treatment: Treatment of seasonal allergic rhinitis; Relief of symptoms associated with seasonal allergic rhinitis
Dosage: SPRAY, METERED;NASAL
DYMISTA family patents
